ChineseInvestors.com, Inc. (OTCQB: CIIX) has been closely monitored for its upside as it competes in the hemp-derived cannabis market. CIIX has launched a cannabidiol (CBD) online store in the free-trade zone of Shanghai and soon it plans to open a brick-and-mortar store in its home market of San Gabriel, California, to market a line of food and nutrition products. However, the bulk of its existing business remains in investor relations, which is growing as the company invests more in personnel and advertising, successfully raising its profile.

CIIX offers a variety of consulting services to Chinese-speaking clients and companies. It offers real-time financial information and educational services in Chinese language character sets. It also provides consulting services to smaller companies seeking to go public. It has clients on the NYSE, NASDAQ, and OTCQB markets. During the quarter ended February 28, 2017, the bulk of the company’s revenues were from its investor relations activities.

The development of new roadshows and multimedia presentations has helped CIIX grow public company clients, building the company’s brand and reputation. CIIX said its gain in investor relations for the period was due to its hiring of more professionals to service public company clients and improve its service quality. The company increased the amount of its advertising to raise its visibility in different cities and languages.

For the three and nine months ended February 28, 2017, the company reported sharp increases in its sales within investor relations, tripling and doubling its revenues for the three-month and nine-month periods, respectively. A SeeThruEquity Report on CIIX of March 2017 (http://dtn.fm/SDJ3f) positively noted the gain in CIIX’s high margin investor relations business.

One factor in its higher profile has been the airing of its weekly TV show via Phoenix Television, which broadcasts the program on its Phoenix North America Chinese Channel. This is a popular, subscriber-only media platform aimed at the Chinese-speaking community in the U.S.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

In view of the current global water crisis, which has reportedly left approximately 783 million people without access to clean, safe water (http://dtn.fm/6HDv4), the existence of a process for reclaiming previously unavailable water would be quite a game-changer, and it just so happens that one company has pioneered just such a process.

Hydration Company of PA (HCPA), a subsidiary of Converde Energy USA, Inc. (OTC: XFUL), d/b/a American Energy Partners, Inc., is focused on sourcing, implementing and distributing reclaimed water at a profit. HCPA has a competitive edge in its pure volume of reclaimed water and its access to low-cost treatment with high flow rates and highly concentrated solids through technologies from XFUL’s partners.

HCPA offers a pioneering solution for locating, procuring, treating and distributing water using a patent-pending process that results in cleaner water and a safer environment. This innovative process can alleviate drought conditions by enabling access to water that was previously unavailable.

Due to the volume and flexibility of the model HCPA has established through its patent-pending methodology and conveyance procedures, the company is poised to immediately and effectively gain market share, since large corporations desire access to a single source that can provide massive amounts of reclaimed water in spite of drought conditions.

The exciting applications for HCPA’s solution include oil and gas, pipelines, mining, utilities, municipalities and landowners. The company plans to operate out of a number of predetermined sites within the United States, which will vary in terms of geography, storage and water quality. These sites will facilitate augmentation or the ability to mitigate during pass-by conditions, and the augmentation of existing water flow will allow the company to supply everyday water as well as providing additional waters to the system in low-flow conditions. This represents a particularly valuable piece of HCPA’s model, as customers will have the ability to consume at their intake up to the maximum docketed withdrawal regardless of how long or severe a drought may be, giving the customers pass-by exemption.

This is how HCPA’s model works:

• Region-wide hydrological studies are conducted to identify the largest pools of non-potable water
• Access and control are gained to these mines through contracts with current owners
• Final hydrology and engineering studies are performed
• A filtration system is installed with all the needed permits
• A dynamically adjustable turnkey system is deployed, allowing HCPA to execute its treatment and distribution model through the company’s proprietary conveyance system

The ability to tap into previously unusable sources of water is certainly an exciting prospect, and one that could address and solve limitations in a variety industries and areas.

For more information, visit the company’s website at www.AmericanEnergy-Inc.com

Let us hear your thoughts: Converde Energy USA, Inc. Message Board

Experts say China could soon look to import refined metal as its available zinc concentrate continues to fall, per a May 2013 Economic Times report (http://dtn.fm/AZ9iv). The falling demand there for steel galvanization is partly to blame; a national crackdown on industrial pollution is helping to drive this decline as well. A decline in refined zinc output from 43,400 tonnes in March 2017 to 41,300 tonnes in April 2017 has been noted by the National Bureau of Statistics, and refined metal production has been affected by major mine closures in Australia and Ireland. In contrast to Chinese production cuts, Kootenay Zinc Corp. (CSE: ZNK) (OTCQB: KTNNF) has stepped up its exploration efforts to meet a global demand for zinc imports.

In a recent press release (http://dtn.fm/Gaw40), the company reported that China boosted its refined zinc imports 21 percent year-over-year while, according to Reuters, zinc ore and concentrates shipments rose 44 percent. These are just a few statistics proving the importance of Kootenay Zinc Corp.’s step up of zinc exploration. The Vancouver-based company is expanding its exploration program at its Sully Property, which is 18 miles east of one of the world’s largest mineral deposits, the legendary Sullivan Mine.

Although the renowned Sullivan Mine closed in 2001 after nearly 100 years in operation, geological data thus far suggests Kootenay Zinc’s Sully Project shares many of the same geological features. These are known for sedimentary exhalative, or SEDEX deposits, that fed the original mine’s 17 million tons of lead and zinc obtained over its operating life. Both locations also reside in the same basin; the company has already seen evidence of a lead-zinc soil anomaly cause by a buried deposit. Minerals may be being leaked up through faults and dispersed amongst the till and alluvium.

An aerial survey also found magnetic anomalies up to two miles long in the area. Exploration efforts continue as these nearly coincide with gravity anomalies. A drilling effort in 2004 may have missed the main deposit site by about 100 meters, according to downhole readings of the local magnetic field and temperature, taken in 2014. Testing has continued into June 2017, when a Kootenay Zinc Corp. exploration update (http://dtn.fm/ec7ES) revealed that scientific observations were ongoing. These included gravity surveying, soil geochemistry sampling, and interpretation and mass modeling. In addition to drilling preparations, road and access preparations were ongoing at the site. The company has been focused on the E3 drilling target, which appears to be a more attractive drilling target compared to the extensively measured and analyzed E1 site.

In fact, outcrop samples have been taken from multiple sites for assay; at two of them, zinc values were above 10,000 parts per million, per a soil geochemical survey in June. Several other samples at the base of the slope were in the 150 to 300 parts per million range. The Sully property is currently 1,375 hectares, or nearly 3,398 acres, in size, and located in British Columbia, where Kootenay continues its mineral exploration and development efforts.

To find out more about Kootenay Zinc Corp. and the company’s exploration efforts at Sully, visit www.KootenayZinc.com

Let us hear your thoughts: Kootenay Zinc Corp. Message Board

Patriot One Technologies, Inc. (TSX.V: PAT) (OTCQB: PTOTF) is taking steps to commercialize its PATSCAN™ CMR technology, which features an innovative radar technology that can detect concealed weapons such as knives, guns, grenades, and suicide vests. The microwave radar system can identify moving targets – individuals who are carrying concealed weapons. Recently featured in a June article (http://dtn.fm/3Nw6n), the company plans on making the system available to commercial markets to help fight terrorism and other security issues throughout the world. Researchers at McMaster University, based in Hamilton, Ontario, have joined forces with the Patriot One team to boost the product’s path to commercialization.

PATSCAN is the next-generation version of NForce CMR1000, a popular and award-winning software and radar system. It has been developed and improved with the help of the university’s research team. The result is a portable device and software solution that can be used by security personnel at the civilian and military levels. PATSCAN has been engineered to detect metal content, using software that can recognize the wavelength patterns of weapons, and compare them to the signatures of known weapons in real time.

Thanks to its small size, the system can be concealed in a doorway, hallway, or in any public venue such as an airport, stadium, or school. Individuals are unaware of the device’s presence or that it is scanning them. Rather than generate a scan as many traditional security systems do, this system automatically relays an alert to security personnel. So far, it has a 93 percent accuracy rate for identifying the entry of an active threat. Its current range is 6.5 feet.

The entire radar-based PATSCAN is contained in a small semiconductor chip. This integrated circuit is similar to microwave radar the military has used for years. It has also enabled more financially practical applications, so other systems have been developed using such small circuits as well. These include intrusion alarms, police speed meters, door openers, and motion detectors. Microwave radar offers a very fine resolution, so it can detect small objects, and some versions integrate multiple receivers, adding fine precision and wide-angle detection.

In addition, the Patriot One-McMaster University solution avoids the pitfalls of current technologies. Present security systems at, for example, airports, use X-rays and CT scans. With PATSCAN, there are no privacy or health concerns, operator errors, or false positives. Individuals do not have to comply with being scanned or searched, nor do they have to take the time to be processed. The entire scanning procedure is inconspicuous to the individual being probed. Plus, an assailant cannot plan a way to avert the radar, as they often try with perimeter security.

Many facilities have sought out detectors that meet cost, space, and location requirements, in addition to those that are simple to use. The need to be accurate despite interference from metal ordinarily carried by people is high as well. Patriot One’s near-field radar solution addresses all the concerns of standard security systems, and it is currently in the process of commercialization.

For more information, visit the company’s website at www.Patriot1Tech.com

For more information, visit the company’s website at www.Patriot1Tech.com

Offering high-quality voice, data, and marketing solutions that help businesses focus on their core operations, Crexendo, Inc. (OTCQX: CXDO) is a competitive local exchange carrier (CLEC) cloud services company that offers award-winning cloud telecommunications, broadband Internet, and other cloud business services. The company provides critical voice and data technology infrastructure for startups, small and medium-sized business (SMB), and small enterprise markets, offering enterprise-caliber cloud services at affordable monthly rates. The company’s world-class services help businesses significantly increase their productivity, and Crexendo is payment card industry-compliant and CLEC-licensed for its cloud web, telecommunications, and network services.

Guided by a team of industry leaders, Crexendo is dedicated to maintaining secure and reliable cloud systems. Beginning with a cutting-edge data center that has multiple redundancy levels and the very best security defenses, Crexendo epitomizes the very highest standards of security and reliability.

Crexendo’s cloud-based phone systems transcend standard phone systems, providing businesses with advanced calling features that cost significantly less. Businesses get the features they need and a full array of productive telecommunication tools, but in the cloud and at a lower price point.

Through Crexendo Mobile, businesses are able to revolutionize their productivity with a simple download. Crexendo Mobile enables businesspeople to access all the features of their office phone right on their existing mobile device, which lets them seamlessly continue their business communications from office to home and everywhere in-between. Crexendo Mobile can also be downloaded to other wireless devices, including tablets. Crexendo Mobile lets individuals make and take calls using their office phone number, showing that office number as their caller ID. This innovative solution additionally separates business voicemails from personal messages and lets users listen to business-related voice messages in any order via visual voicemail. Users can view call times, call dates, and make return phone calls using Crexendo call logs, and calls can be made via 3G/4G networks so that monthly cell phone minutes aren’t impacted. What’s more, Crexendo lets businesspeople traveling internationally call the United States for free using CrexMo.

Crexendo’s cutting-edge solutions give businesses unparalleled freedom, cutting the cord between the office and the outside world and improving productivity like never before.

For more information, visit the company’s website at www.Crexendo.com

Algae Dynamics Corp (OTCQB: ADYNF) is focused on developing proprietary research and products involving botanical oils derived from cannabis and algae.

The original core of the company’s product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed at developing products that combined the health benefits of algae and cannabis oils. Capitalizing on the burgeoning demand for cannabis oil and other smoke-free alternatives to marijuana consumption will help support ongoing initiatives to create and market research-driven product formulations.

Although the company is publicly traded in the U.S., business is conducted in Canada with no exposure to U.S. federal regulation involving cannabis. The Canadian cannabis oil extraction marketplace is projected to grow from C$1 million in 2015 to C$1.7 billion in 2020, which is more than a 1,000-fold increase. With the Government of Canada indicating a target date for full legalization on or before July 2018, numerous opportunities for sales in extracts and oils will open up very soon.

Using Colorado as a comparable example, a study performed by Mackie Research Capital found that 45% of dried marijuana users in the state would eventually convert to marijuana extracts and oils. This is because most consumers taking cannabis for medical purposes are increasingly looking for delivery systems that do not involve smoking marijuana. The market’s attractiveness can be further realized when considering that the Canada’s licensed producer marketplace is far less competitive with 45 current licensed producers for the whole country vs. 624 licensed cultivators in Colorado.

Collaborating with prominent Canadian universities is a core part of the Algae Dynamics’ plan to bolster cannabis extraction expertise, develop premium products and add to its portfolio of intellectual property. Through its agreements with the University of Waterloo and the University of Western Ontario, the company is focusing primarily on the use of extracts from cannabis oil and algae oil in the context of cancer as well as the development of new pharmacotherapies for mental health.

Near-term goals include expanding research and development work with existing and new Canadian universities, securing supply/service agreements with licensed producers, and submitting an application to Health Canada to become a licensed producer of medical marijuana and ultimately have a license to sell products derived from cannabinoids. Algae Dynamics also owns a proprietary technology for the cultivation of low cost, highly pure algae biomass, which will be developed as a vertical integration strategy in the future to support the need to source algae oil for research-driven product formulations. The management team leading these initiatives has nearly a century of beneficial experience spanning from management and process experience to successful fund raising and commercialization.

As part of its key objective to be the #1 research Canadian cannabis oil research-driven product formulator, the company has also formed a strong team of scientific and strategic advisors that complement ongoing R&D relationships and initiatives. Individuals who support the company’s initiatives include Dr. Jonathan Blay PhD, FRSB, FIBMS, Csci, CBiol, who performs research and product development on cannabis oil and its constituents in the context of colorectum, pancreas, breast and prostate cancers; and Dr. Steven Laviolette, BSc, PhD, who performs research and product development on cannabis oil and its constituents in the context of depression, post-traumatic stress disorder, anxiety and schizophrenia.

With such a strong foundation laid in the areas being pursued, Algae Dynamics is well positioned to execute on its carefully developed business plan to fast-track to revenue growth while having a longer-term strategy to build a sustainable enterprise-building opportunity in a rapidly expanding market.

For more information, visit the company’s website at www.AlgaeDynamics.com

Let us hear your thoughts: Algae Dynamics Corp. Message Board

Despite the fire-breathing from Attorney-General Jefferson Beauregard Sessions III, there is a distinct feeling that marijuana has entered the mainstream now that Goldman Sachs has initiated coverage on GW Pharma (NASDAQ: GWPH). GW Pharma is the biopharmaceutical that developed the cannabinoid-derived Sativex to treat spasticity due to multiple sclerosis (MS), now approved by regulatory authorities in 29 countries. The success of GW Pharma and other pharmaceutical companies focused on cannabinoid research has produced an exciting new field with a lot of promise, cannabis biotech, and InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is staking a position in that emerging market. The Vancouver, Canada-based outfit is a pre-clinical stage biopharmaceutical company that is currently testing cannabinoid derivatives to treat epidermolysis bullosa and glaucoma and a full pipeline of other drug candidates.

Cannabinoids are turning out to be big business. GW Pharma presently has a market cap of around $3.0 billion, yet Goldman Sachs, in that initial report, intimated the company might be worth more. It set a target price of $189 on the stock, currently trading at just above $116, which would value the company at close to $5 billion. GW Pharma is set to file a New Drug Application (NDA) with the FDA in the first half of 2017 for Epidiolex, the company’s cannabis-based treatment for rarer forms of epilepsy.

Axim Biotechnologies, Inc. (OTCQB: AXIM) is another player showing value. The company owns the patent for chewing gum as a delivery method for cannabinoids, which it has developed into two separate products. Its current market cap is about $500 million. Cara Therapeutics, Inc. (NASDAQ: CARA), meanwhile, is researching therapies that target the CB1 and CB2 cannabinoid (CB) receptors. Its most advanced CB compound, CR701, is in preclinical development. The company’s market value is about $556 million. Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) has a different focus. This biotech is studying synthetic cannabinoid therapeutics across multiple therapeutic areas. It has a market cap of over $220 million.

Research into the properties of cannabis was galvanized after Raphael Mechoulam and Yehiel Gaoni first isolated delta-9-tetrahydrocannabinol (THC) in 1963. Then, cannabinoid research became an even more exciting area of scholarship in 1992 when the first endocannabinoid, anandamide, was discovered. An endocannabinoid is a cannabinoid that is manufactured by the body. The fact that our bodies were producing the very same substances found in cannabis raised some very interesting questions.

Now we know that residing within most life forms (basically everything on our planet with the exception of insects) there is an extensive molecular signaling network known as the endocannabinoid system, which controls many functions. It has been said that ‘the endocannabinoid system is possibly the single-most important system within our entire bodies – responsible for maintaining homeostasis’ (http://dtn.fm/8Q5dt). Consequently, the aim of much cannabinoid research has been to provide cannabinoids to the body when, for one reason or another, the body fails to provide adequate quantities.

Presently, InMed Pharmaceuticals has two promising drug candidates undergoing pre-clinical trials. The first, INM-750, is for the treatment of a rare genetic connective tissue disorder called epidermolysis bullosa (EB), which affects roughly one out of every 20,000 births in the United States. There is an estimated patient population of about 25,000 with this condition in the U.S. alone. Globally, the market potential is about $1.0 billion.

The second drug, INM-085, treats glaucoma, a leading cause of blindness. INM-085 works by reducing the elevated intra-ocular pressure that is often associated with glaucoma. The National Institutes of Health estimates that more than three million Americans currently have glaucoma, and that the disease has blinded more than 120,000. INM-085 has a global market potential of close to $6.0 billion. Cannabinoid research is proving to be a truly exciting field.

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board

Net Element, Inc. (NASDAQ: NETE) is seen reaching revenues of $75 million in 2018 by a Zacks Research Report issued in May 2017 (http://nnw.fm/wV8IN). In the Zacks Small-Cap Research Report, it is estimated that the company’s sales will reach $63 million in 2017 and $74.6 million in 2018. Net Element reported actual revenues of $54.3 million in 2016.

Net Element is a high technology financial group that digitally processes transactions in an omni-channel environment in what is becoming a world of cashless transactions. It processes the electronic transactions from both point-of-sale and mobile devices.

Driving this forecast revenue growth is a continuation of the increases from Net Element’s North American Transaction Group. It is seen by Zacks as delivering 41% and 20% year-over-year growth in 2017 and 2018, respectively, for a total of $64.2 million in sales in 2018. By far, it remains as the single biggest contributor of the three components in the Net Element company. The other two are mobile payments and PayOnline.

Zacks has an investment thesis that incorporates the belief that New Element is a growth company in the payments industry that should benefit from mobile and online payments from the U.S., Russia and the Middle East. Eventually, Zacks’ research said, these payments are expected to achieve a global reach. The other thesis by the research company is that Net Element’s Aptito line provides differentiation and value-added services to its generic card processing business.

By sacrificing short-term profits and placing its focus on long-term growth, the company is creating a “long tail, future profitability and higher margins,” the report said. “As long as public markets are willing to fund the company through equity, this strategy may play out in future years.”

Zacks added that NETE’s PayOnline is being certified in the U.S. in the near-term future. The company’s Unified Payments would then be able to implement the platform. By not using third party payments at that time, NETE could then save costs and increase its margins. Net Element believes that as many as 15% of its Unified Payments transactions would be impacted positively, per the report.

For more information, refer to www.NetElement.com

Moxian, Inc. (NASDAQ: MOXC) offers investors a high risk-high reward opportunity in China’s online-to-offline (O2O) marketplace, and the key is the high gross margin percentages of the company’s revenues, according to the SeeThruEquity (http://nnw.fm/dee5W) research report on the company. Shenzhen, China-based Moxian has a gross margin of 77.4% — second-highest of all of its significantly higher market cap competitors, the report says.

MOXC is a development stage company that’s currently executing its marketing strategy of converting its two O2O platforms from unpaid to paid. Moxian+ is a business platform which is already serving, at no charge, some 30,000 small market enterprises (SMEs). Its other app is Moxian User, a consumer app which already has some 300,000 users. The marketing effort is to convert the free users on both apps to paid, then gain more revenues from paid subscriptions, mobile advertising, transaction and licensing fees and OEM and distribution fees.

SeeThruEquity notes that MOXC believes it can achieve a revenue total of $25 million in 2018. The company anticipates revenue of $11 million in 2017. Key to achieving its profit goals is MOXC’s high profit margins from its own sales and mobile advertising, as the company believes it would realize lower margins from third party transactions.

Within the O2O market, MOXC may face formidable competitors which are significantly larger in terms of market cap, but MOXC boosts high profit margins. As previously indicated, its 77.4% gross margin percentage is the second-highest in a field that includes seven other firms. SeeThruEquity believes that Moxian will invest in technology, sales and marketing to differentiate its products in this market. It is seen as also leveraging the existing customer base of its merchant partners.

For more information, visit www.Moxian.com

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF), a pre-clinical stage biopharmaceutical company that specializes in the development of therapies through research and development into the pharmacology of cannabinoids and drug delivery systems, continues to get positive media coverage of ongoing operational developments, propelled by the company’s impressive leadership team.

Insider Financial highlighted InMed Pharmaceuticals as a “Cannabis Runner” in an article back in January, stating that “This is the kind of company that needs to maintain a positive news flow in order to keep investors interested.” More recently, Forbes released an article describing the company as “more than just another cannabis drug company”. This was due to the excitement surrounding the development of its proprietary cannabinoid manufacturing system and sought-after database, its biosynthesis for cannabinoids that is similar to that used to create synthetic insulin, as well as its ability to leverage some of the leading experts in the pharmaceutical industry.

Although the company’s pipeline is expected to generate a significant amount of attention in 2018, InMed Pharmaceuticals’ manufacturing system and database are catching the eye of investors and biotech companies. THC and CBD have, of course, been used for treating medical conditions, but there are now more than 90 different cannabinoids identified in one plant, and all of these are thought to serve various purposes. InMed has managed to plug these different cannabinoids into its system, allowing the bioinformatics compounds to test them against various illnesses and drug compounds, matching the right cannabinoids to help fight specific diseases.

This tool has helped the company identify two therapies, one for epidermolysis bullosa (EB), a rare skin disease found in children, and one for glaucoma, a degenerative condition that causes damage to a person’s optic nerve. In addition to all of the above, the company has now developed a method of biosynthesis similar to that used to create synthetic insulin, but for cannabinoids. This process is not only cheaper, but quicker, and it gives access to cannabinoids that are not currently profitable to turn into drugs.

These are all developments that owe their success to leadership that comprises some of the world’s most experienced professionals in the pharmaceutical, drug discovery, cannabinoid therapy, and R&D industries (http://dtn.fm/DTx95).

For more information, visit the company’s website at www.InMedPharma.com

Let us hear your thoughts: InMed Pharmaceuticals, Inc. Message Board